Astellas Pharma Inc. (4503.T) — Available-Data Snapshot
Updated Sep 3, 2026 · available-data snapshot · descriptive, not a DCF, not advice
We don't publish a discounted-cash-flow fair value for Astellas Pharma Inc. (4503.T) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
On the numbers we do have, 4503.T trades at a recent price of ¥2,417, a market capitalisation of about ¥4,333,714,276,352, sitting 74% of the way up its 52-week range (¥1,558–¥2,717), on the Tokyo.
The standard alternative to a DCF is relative valuation — comparing 4503.T's trading multiples against a sector benchmark. Here that gives P/E of 14.9× (cheaper than the peer median of 38.9×); Fwd P/E of 31.9× (richer than the peer median of 16.1×); P/B of 2.2× (cheaper than the peer median of 8.4×); P/S of 1.9× (cheaper than the peer median of 6.8×); EV/EBITDA of 6.9× (cheaper than the peer median of 17.1×); Dividend yield of 3.3% (cheaper than the peer median of 2.2%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. 4503.T shows a price-to-book (P/B) of 2.23 and book value of ¥1,083 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. 4503.T is in a mixed trend, trading -11.0% from its 52-week high. Over the past year the stock is +43.6%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
Relative valuation — 4503.T vs peers
| Multiple | 4503.T | Peer median | |
|---|---|---|---|
| P/E | 14.9× | 38.9× | cheaper than |
| Fwd P/E | 31.9× | 16.1× | richer than |
| P/B | 2.2× | 8.4× | cheaper than |
| P/S | 1.9× | 6.8× | cheaper than |
| EV/EBITDA | 6.9× | 17.1× | cheaper than |
| Dividend yield | 3.3% | 2.2% | cheaper than |
Sector benchmark (bellwethers, not direct competitors).
Asset / book-value view
Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.
Price-based snapshot
Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.
Explore more
Most undervalued stocks (per our valuation) · All valued stocks · Interactive 4503.T viewA descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.